Key Documents

View All Documentation

G0798

GSK1016790A

Name: GSK1016790A
Brand: SIGMA

≥98% (HPLC), solid, TRPV4 channel agonist

Synonym(s):

GSK101, (N-((1S)-1-{[4-((2S)-2-{[(2,4-Dichlorophenyl)sulfonyl]amino}-3-hydroxypropanoyl)-1-piperazinyl]carbonyl}-3-methylbutyl)-1-benzothiophene-2-carboxamide

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):

C₂₈H₃₂Cl₂N₄O₆S₂

CAS Number:

942206-85-1

Molecular Weight:

655.61

UNSPSC Code:

12352200

PubChem Substance ID:

329799716

NACRES:

NA.77

MDL number:

MFCD12912413

Assay:

≥98% (HPLC)

Form:

solid

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Properties

Product Name

GSK1016790A, ≥98% (HPLC)

Quality Segment

100

assay

≥98% (HPLC)

form

solid

color

white

solubility

DMSO: >10 mg/mL

originator

GlaxoSmithKline

storage temp.

−20°C

SMILES string

CC(C)C[C@H](NC(=O)c1cc2ccccc2s1)C(=O)N3CCN(CC3)C(=O)[C@H](CO)NS(=O)(=O)c4ccc(Cl)cc4Cl

InChI

1S/C28H32Cl2N4O6S2/c1-17(2)13-21(31-26(36)24-14-18-5-3-4-6-23(18)41-24)27(37)33-9-11-34(12-10-33)28(38)22(16-35)32-42(39,40)25-8-7-19(29)15-20(25)30/h3-8,14-15,17,21-22,32,35H,9-13,16H2,1-2H3,(H,31,36)/t21-,22-/m0/s1

InChI key

IVYQPSHHYIAUFO-VXKWHMMOSA-N

Description

Application

GSK1016790A has been used:

to stimulate transient receptor potential vanilloid 4 (TRPV4)-mediated currents in Xenopus laevis oocytes
to stimulate cells in Ca²⁺ level measurement in human retinal capillary endothelial cells (HRCECs)
to study the role of TRPV4 channels in brain injury after intracerebral hemorrhage (ICH)
to trigger the opening of TRPV4 channels in bovine nucleus pulposus cells or Hanks′ Balanced Salt Solution

Biochem/physiol Actions

GSK1016790A is a novel and potent TRPV4 channel agonist.

GSK1016790A is a novel and potent TRPV4 channel agonist. The TRPV4 (transient receptor potential vanilloid 4) member of the TRP superfamily has been implicated in numerous physiological processes. GSK1016790A elicited Ca²⁺ influx in mouse and human TRPV4 expressing HEK cells (EC₅₀ values of 18 and 2.1 nM, respectively), and evoked a dose-dependent activation of TRPV4 whole-cell currents at concentrations above 1 nM. It is 300 fold more potent than 4a-PDD (Cat. No. P8014).

Features and Benefits

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Still not finding the right product?

Explore all of our products under GSK1016790A

Storage Class

11 - Combustible Solids

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c